A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Launched by TERNS, INC. · Feb 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called TERN-601 to see how well it works, how safe it is, and how well people tolerate it. The trial is for adults aged 18 to 75 who are overweight or have obesity. To be eligible, participants need to have a body mass index (BMI) of at least 27 (with some health issues) or at least 30, and they should have maintained a steady weight for at least three months. Importantly, people with diabetes or certain other health conditions won't be able to join the study.

Participants in this study will take TERN-601 or a placebo (a pill without the active medication) for a specific period. A placebo helps researchers understand how much of the effects come from the medication itself versus people's expectations. Throughout the trial, participants will be monitored for any side effects and overall health. The goal is to find out if TERN-601 can help with weight management in a safe and effective way. If you or someone you know fits the criteria and is interested, this could be an opportunity to contribute to important research in obesity treatment.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Female or male aged 18 to 75 years
• 2. Body mass index (BMI) of:
• • 1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2
• • OR
• • 2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
• • 3. HbA1c \< 6.5%
• • 4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)
• Key Exclusion Criteria:
• • 1. Have diabetes mellitus
• • 2. Have obesity induced by medication or other diagnosed endocrinologic disorders
• • 3. Have had or are planning surgical treatment or device-based therapy for obesity
• • 4. Lifetime history of suicide attempt